Followers | 31 |
Posts | 2649 |
Boards Moderated | 0 |
Alias Born | 10/28/2013 |
Wednesday, April 27, 2016 2:45:11 AM
flipper44 Member Level Tuesday, 04/26/16 12:11:58 PM
Re: Doc logic post# 59742
Post #
59745
of 59783 Go
Doc logic,
That may be the case, but my point in the thread we are discussing is this.
IMHO.
1. TIL count does not correlate with survival when standard of care is used. -- UCLA
2. TIL count does correlate with survival when DCVax-L is used.
3. ALC does not correlate with survival when SOC is used.
4. ALC does correlate with additional survival when immunotherapy (CI) is used, but we are waiting to see if this is an additional biomarker for DCVax-L.
The point is that with TIL, Dr. Prins states that, as a simple explanation, DCVax-L helps reactivate an immune response in tumors that are immunogenic but previously suppressed an immune response.
With regard to absolute lymphocyte count (peripheral blood lymphocyte count), patients in the DCVax-L trial have an absolute lymphocyte count ≥1,000/mm3. This means they do not start DCVax-L treatment in patients with lymphopenia. In other words, patients are more likely to still be able to mount an immune response, which may, we shall see be exploited by DCVax-L to fight the cancer.
You are taking it a step further and assuming I'm saying the ALC means there is an active response against the tumor -- prevaccination. I'm not saying that is necessarily the case. I'm just saying the inclusion criteria used patients that are more likely to have immune systems against the cancer activated and/or reactivated by DCVax-L and/or made more robust.
(This is not a black and white issue, because even where there is lymphopenia, the chemoradiation may have simultaneously temporarily compromised regulatory immune cells and thus allowed DCVax-L time to get a foothold -- sometimes. That is an area where there is controversy in the literature, and I believe the phase III trial might provide more data on that issue.)
Now add the recent UCLA paper, it's not just TIL count, but also, "significant overlap in sequence between T cell receptors in the tumor and in the peripheral blood was correlated with extended survival." This additional correlation was found when DCVax-L was used. Interestingly, even some patients that did not have overlap prior to DCVax-L treatment, developed it afterwards.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM